Aurinia Pharmaceuticals (AUPH) Set to Post Quarterly Earnings on Tuesday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.22 per share and revenue of $83.61 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $58.57 million during the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. On average, analysts expect Aurinia Pharmaceuticals to post $0.91 EPS for the current fiscal year and $1.05 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $17.04 on Tuesday. Aurinia Pharmaceuticals has a 12-month low of $11.89 and a 12-month high of $19.25. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The company has a market cap of $2.27 billion, a PE ratio of 7.44 and a beta of 1.60. The stock has a 50-day moving average price of $16.37 and a 200-day moving average price of $15.60.

Wall Street Analysts Forecast Growth

AUPH has been the subject of a number of research reports. Royal Bank Of Canada boosted their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Zacks Research cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, TD Cowen raised their price target on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.75.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.